Chronotherapy for oral squamous cell carcinoma -Attempt to reduce side-effects associated with DCF chemotherapy-

Chronotherapy for oral squamous cell carcinoma -Attempt to reduce side-effects associated with DCF chemotherapy- - Chronotherapy of DCF chemotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006713

Enrollment

Registered

2011-11-12

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral squamous cell carcinoma

Interventions

1. Normal Regimen group: Dosing with docetaxel and cisplatin at morning 2. Chronotherapy regimen group: Dosing with docetaxel and cisplatin at evening

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Stage III, IV an oral squamous cell carcinoma 2. General condition (ECOG Performance Status) is 0-2 3. Satisfy the following criteria within 14 days before registration: # Leukocyte: 3,000/mm3 <= # Neutrophil: 2,000/mm3 <= # Hemoglobin: 10g/dL <= # Platelet: 100,000/mm3 <= # AST and ALT: =< 100 # Total Bilirubin: =< 1.5 mg/dL # Creatinine clearance: 60ml/min <=

Exclusion criteria

Exclusion criteria: 1. Severe hypersensitivity to study drugs 2. With active bacterial and fungal infections 3. Have serious complications (such as chronic obstructive pulmonary disease, pulmonary fibrosis, angina requiring treatment, heart failure) 4. Severe diarrhea 5. Pregnant women or who have a hope of pregnancy 6. Doctor judged unsuitable for participating in this study

Design outcomes

Primary

Measure	Time frame
Incidence of Grade 3 or higher neutropenia	—

Countries

Japan

Contacts

Public ContactTadahide Noguchi

Jichi Medical University Department of Oral & Maxillofacial Surgery

tadahide.noguchi@gmail.com0285-58-7390

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026